In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.
In this portion of MHE's survey, respondents gave their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise.
Majority of respondents (26%) said Imcivree (setmelanotide), a drug for rare forms of obesity, would have the most promise to reduce morbidity and mortality when asked. Twenty-two percent of respondents said Oxlumo (lumasiran), a drug that treats primary hyperoxaluria type 1, shows more promise. Remaining respondents were for Zokinvy (lonafarnib) (22%), which is for rare conditions related to premature aging; 21% were for Orgovyx (relugolix), for prostate cancer; and 10% were for Evrysdi (risdiplam), a drug for spinal muscular atrophy.
When asked which drug in the pipeline shows more promise, participants responded with Farxiga (dapagliflozin), which treats chronic kidney disease in adults with or without type 2 diabetes, with a percentage at 35%. Roxadustat, a drug that treats anemia associated with chronic kidney disease, followed shortly behind at 31%. Participants (24%) also said Teplizumab, which is used for the prevention of type 1 diabetes, shows promise; while Valoctocogene roxaparvovec, a drug for severe hemophilia A, trailed behind at 24%.
Just over 225 people responded to our online survey between April 5 and May 10.